B2M and B-cell chronic lymphocytic leukemia: Our study demonstrates that elevated B2M plasma levels retain their prognostic value for OS in Binet A stage CLL patients with concurrent compromised kidney function diagnosed in both treatment eras of chemoimmunotherapy and novel agents.